CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
88.30
0.45%
Market Trading Hours* (UTC) Open now
Closes on Thursday at 15:30

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.40
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.021388 %
Charges from full value of position ($-4.06)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.021388%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000834 %
Charges from full value of position ($-0.16)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000834%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Biomerieux SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 88.65
Open* 88.95
1-Year Change* 9.01%
Day's Range* 88.05 - 88.95
52 wk Range 77.48-104.00
Average Volume (10 days) 119.27K
Average Volume (3 months) 1.72M
Market Cap 10.97B
P/E Ratio 28.46
Shares Outstanding 118.12M
Revenue 3.70B
EPS 3.26
Dividend (Yield %) 0.91753
Beta 0.04
Next Earnings Date Mar 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 27, 2023 88.65 -1.00 -1.12% 89.65 90.45 88.55
Sep 26, 2023 89.85 0.15 0.17% 89.70 90.40 88.55
Sep 25, 2023 90.35 0.10 0.11% 90.25 90.65 89.55
Sep 22, 2023 90.65 2.15 2.43% 88.50 91.10 88.50
Sep 21, 2023 89.85 -1.60 -1.75% 91.45 91.80 89.85
Sep 20, 2023 92.40 2.10 2.33% 90.30 92.60 90.30
Sep 19, 2023 90.05 -0.80 -0.88% 90.85 91.15 89.65
Sep 18, 2023 91.35 0.15 0.16% 91.20 92.65 90.80
Sep 15, 2023 91.20 -1.40 -1.51% 92.60 93.50 90.90
Sep 14, 2023 92.55 1.35 1.48% 91.20 93.05 91.20
Sep 13, 2023 91.50 1.70 1.89% 89.80 91.50 89.10
Sep 12, 2023 90.25 -1.20 -1.31% 91.45 92.00 90.25
Sep 11, 2023 91.80 0.00 0.00% 91.80 92.55 90.85
Sep 8, 2023 91.95 -0.55 -0.59% 92.50 92.85 91.25
Sep 7, 2023 92.30 1.10 1.21% 91.20 92.55 90.90
Sep 6, 2023 91.70 -1.60 -1.71% 93.30 93.45 90.65
Sep 5, 2023 94.15 -0.95 -1.00% 95.10 95.80 93.70
Sep 4, 2023 95.40 0.85 0.90% 94.55 96.45 94.55
Sep 1, 2023 94.40 -0.10 -0.11% 94.50 94.65 88.05
Aug 31, 2023 96.20 -1.00 -1.03% 97.20 97.70 95.65

Biomerieux Events

Time (UTC) Country Event
Thursday, October 26, 2023

Time (UTC)

06:30

Country

FR

Event

Q3 2023 Biomerieux SA Corporate Sales Release
Q3 2023 Biomerieux SA Corporate Sales Release

Forecast

-

Previous

-

Time (UTC)

10:59

Country

FR

Event

Q3 2023 Biomerieux SA Corporate Sales Call
Q3 2023 Biomerieux SA Corporate Sales Call

Forecast

-

Previous

-
Wednesday, March 6, 2024

Time (UTC)

07:30

Country

FR

Event

Full Year 2023 Biomerieux SA Earnings Release
Full Year 2023 Biomerieux SA Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3589.1 3376.2 3118.2 2674.8 2421.3
Revenue 3589.1 3376.2 3118.2 2674.8 2421.3
Cost of Revenue, Total 1580.4 1375.4 1364.5 1208.2 1119
Gross Profit 2008.7 2000.8 1753.7 1466.6 1302.3
Total Operating Expense 3001.9 2591.3 2566 2304.1 2075.2
Selling/General/Admin. Expenses, Total 954.7 815.6 789.3 749.8 643.1
Research & Development 446.6 385.8 398.8 374.3 326.9
Depreciation / Amortization 76.6 59.7 17.5 17.9 17.5
Unusual Expense (Income) -0.6 0.6
Other Operating Expenses, Total -56.4 -44.6 -4.7 -46.1 -31.3
Operating Income 587.2 784.9 552.2 370.7 346.1
Interest Income (Expense), Net Non-Operating -4.3 -11.7 -29.1 -23.8 -26.7
Other, Net -2.3 1.3 1.2 0.7 -1.9
Net Income Before Taxes 580.6 774.5 524.3 347.6 317.5
Net Income After Taxes 440.5 598.9 402.8 269.8 252.4
Minority Interest 11.8 2.9 1.7 3.1 1.1
Equity In Affiliates 0 -0.7 -0.2 0 0.2
Net Income Before Extra. Items 452.3 601.1 404.3 272.9 253.7
Net Income 452.3 601.1 404.3 272.9 253.7
Total Adjustments to Net Income 0.1 0 0.1 -0.1 2.8
Income Available to Common Excl. Extra. Items 452.4 601.1 404.4 272.8 256.5
Income Available to Common Incl. Extra. Items 452.4 601.1 404.4 272.8 256.5
Diluted Net Income 452.4 601.1 404.4 272.8 256.5
Diluted Weighted Average Shares 118.441 118.893 118.592 118.609 118.203
Diluted EPS Excluding Extraordinary Items 3.81964 5.05579 3.41 2.3 2.17
Dividends per Share - Common Stock Primary Issue 0.85 0.85 0.62 0.19 0.35
Diluted Normalized EPS 3.81964 5.05189 3.41389 2.3 2.17
Dilution Adjustment 0
Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 1931.1 1658 1802 1574.2
Revenue 1931.1 1658 1802 1574.2
Cost of Revenue, Total 860.4 720 721.6 659.2
Gross Profit 1070.7 938 1080.4 915
Total Operating Expense 1641 1360.9 1383.5 1208.4
Selling/General/Admin. Expenses, Total 514.4 440.3 436.9 379.6
Research & Development 239.3 207.3 204.8 181.5
Depreciation / Amortization 51.7 24.9 44.6 8.3
Other Operating Expenses, Total -24.8 -31.6 -24.4 -20.2
Operating Income 290.1 297.1 418.5 365.8
Interest Income (Expense), Net Non-Operating 2.8 -7.1 -4.7 -7
Other, Net -3.8 1.5 1.3 0.6
Net Income Before Taxes 289.1 291.5 415.1 359.4
Net Income After Taxes 214.2 226.3 322 276.9
Minority Interest 10 1.8 1.8 1.1
Equity In Affiliates 0 0 0.2 -0.9
Net Income Before Extra. Items 224.2 228.1 324 277.1
Net Income 224.2 228.1 324 277.1
Income Available to Common Excl. Extra. Items 224.4 228 324 277.1
Income Available to Common Incl. Extra. Items 224.4 228 324 277.1
Diluted Net Income 224.4 228 324 277.1
Diluted Weighted Average Shares 118.533 118.349 119.1 118.927
Diluted EPS Excluding Extraordinary Items 1.89315 1.92651 2.7204 2.33
Dividends per Share - Common Stock Primary Issue 0.85 0 0.85 0
Diluted Normalized EPS 1.89315 1.92651 2.7204 2.33
Total Adjustments to Net Income 0.2 -0.1 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2216.7 2184.6 1661.6 1438.5 1314.4
Cash and Short Term Investments 552.6 803.5 389.2 275 288.3
Cash 552.6 803.5 313.5 241 239.9
Cash & Equivalents 75.7 34 48.4
Total Receivables, Net 926.9 761 730.4 668.8 607.3
Accounts Receivable - Trade, Net 740.1 590.6 597.9 552.1 491.8
Total Inventory 737.2 620 541.9 494.7 418.8
Other Current Assets, Total 0.1 0.1
Total Assets 5186.6 4605 3927.8 3781.9 3501.6
Property/Plant/Equipment, Total - Net 1369.9 1224.8 1068.6 1025.2 899.1
Property/Plant/Equipment, Total - Gross 2703.9 2447.7 2173.3 2100.9 1899.4
Accumulated Depreciation, Total -1334.1 -1222.7 -1104.7 -1075.7 -1000.5
Goodwill, Net 812.5 669.5 629.4 652.5 619
Intangibles, Net 625 411.5 430.7 508.4 507.2
Long Term Investments 71.2 62 39.9 31.7 59.2
Note Receivable - Long Term 19.8 10.7 10.4 8
Other Long Term Assets, Total 71.5 52.6 86.9 115.2 94.7
Total Current Liabilities 1131.1 955.7 923.8 1170.1 796.3
Accounts Payable 269.4 239.5 207.1 211.9 179.7
Accrued Expenses 372.6 327.4 283.3 262.4
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 187 99.7 128.9 438.6 129.1
Other Current Liabilities, Total 302.1 616.5 260.4 236.3 225.1
Total Liabilities 1582.4 1492.8 1496.7 1578 1572.8
Total Long Term Debt 318.4 362.8 352.4 153.7 524.9
Long Term Debt 318.4 362.8 352.4 153.7 524.9
Deferred Income Tax 53 60.3 105.8 141.2 130.5
Minority Interest 38.7 51.4 50.2 50.7 74.1
Other Liabilities, Total 41.2 62.6 64.5 62.3 47
Total Equity 3604.2 3112.2 2431.1 2203.9 1928.8
Common Stock 12 12 12 12 12
Additional Paid-In Capital 3062.2 2532.1 2204.7 1933.4 1712.2
Retained Earnings (Accumulated Deficit) 410.4 542.5 344.7 207.9 210.1
Treasury Stock - Common -36 -10.3 -23 -3.9 -32.8
Other Equity, Total 155.6 35.9 -107.3 54.5 27.3
Total Liabilities & Shareholders’ Equity 5186.6 4605 3927.8 3781.9 3501.6
Total Common Shares Outstanding 118 118.282 118.16 118.324 117.819
Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 2216.7 2058.4 2184.6 1798.7
Cash and Short Term Investments 552.6 524.2 803.5 493.2
Cash 552.6 524.2 803.5 363.3
Cash & Equivalents 129.9
Total Receivables, Net 926.9 825.7 761 694.5
Accounts Receivable - Trade, Net 740.1 624.2 590.6 542.4
Total Inventory 737.2 708.5 620 611
Total Assets 5186.6 5041.2 4605 4157.2
Property/Plant/Equipment, Total - Net 1369.9 1314.4 1224.8 1135.2
Property/Plant/Equipment, Total - Gross 2703.9 2620.7 2447.7 2306.1
Accumulated Depreciation, Total -1334 -1306.2 -1222.7 -1170.8
Goodwill, Net 812.5 877.5 669.5 642.4
Intangibles, Net 625 667.5 411.5 426.8
Long Term Investments 91 48 62 56.6
Other Long Term Assets, Total 71.5 75.4 52.6 97.5
Total Current Liabilities 1131.1 1020.7 955.7 857.9
Accounts Payable 269.4 243.4 239.5 199.1
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 187 226 99.7 163.2
Other Current Liabilities, Total 674.7 551.3 616.5 495.6
Total Liabilities 1582.4 1572.2 1492.8 1459
Total Long Term Debt 318.4 365.7 362.8 361.5
Long Term Debt 318.4 365.7 362.8 361.5
Deferred Income Tax 53 97.2 60.3 124.7
Minority Interest 38.7 44.9 51.4 50.8
Other Liabilities, Total 41.2 43.7 62.6 64.1
Total Equity 3604.2 3469 3112.2 2698.2
Common Stock 12 12.2 12 12
Additional Paid-In Capital 3062.2 3174.3 2532.1 2528.8
Retained Earnings (Accumulated Deficit) 410.4 183.5 542.5 219.5
Treasury Stock - Common -36 -152.3 -10.3 -16.6
Other Equity, Total 155.6 251.3 35.9 -45.5
Total Liabilities & Shareholders’ Equity 5186.6 5041.2 4605 4157.2
Total Common Shares Outstanding 118 119.507 118.282 118.095
Other Current Assets, Total 0.1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 440.5 598.2 402.7 269.7 255.6
Cash From Operating Activities 475.1 824.7 582.8 407.9 399.7
Cash From Operating Activities 67 58.8 210.8 189.5 177
Non-Cash Items 264.8 176.7 159 45.5 12.3
Cash Taxes Paid 223.5 185.4 115.9 81.6 66.5
Cash Interest Paid
Changes in Working Capital -297.2 -9 -189.7 -96.8 -45.2
Cash From Investing Activities -528.1 -307.3 -265.2 -282.2 -413.1
Capital Expenditures -286.7 -290.1 -277.5 -272.5 -226.4
Other Investing Cash Flow Items, Total -241.4 -17.2 12.3 -9.7 -186.7
Cash From Financing Activities -244.2 -140.6 -176.2 -133.9 43
Financing Cash Flow Items -0.1 -2.4 -23.4 0
Total Cash Dividends Paid -101.2 -73.1 -22.5 -41.3 -40.2
Issuance (Retirement) of Stock, Net -157.2 -17.4 -16.8 0 -22.3
Issuance (Retirement) of Debt, Net 14.3 -50.1 -134.5 -69.2 105.5
Foreign Exchange Effects 38.7 39.2 -34.1 -6.1 -11.8
Net Change in Cash -258.5 416 107.3 -14.3 17.8
Dec 2022 Jun 2022 Dec 2021 Jun 2021
Net income/Starting Line 440.5 226.2 598.2 276
Cash From Operating Activities 475.1 150.9 824.7 285.8
Cash From Operating Activities 67 100.4 58.8 97.2
Non-Cash Items 264.8 -27.4 176.7 -66.4
Cash Taxes Paid 223.5 145.4 185.4 98.1
Changes in Working Capital -297.2 -148.3 -9 -21
Cash From Investing Activities -528.1 -352.3 -307.3 -143.4
Capital Expenditures -286.7 -152.8 -290.1 -143.5
Other Investing Cash Flow Items, Total -241.4 -199.5 -17.2 0.1
Cash From Financing Activities -244.2 -127.8 -140.6 -73.8
Total Cash Dividends Paid -101.2 -101.2 -73.1 -73.1
Issuance (Retirement) of Stock, Net -157.2 -111.3 -17.4 -2.5
Issuance (Retirement) of Debt, Net 14.3 84.8 -50.1 1.8
Foreign Exchange Effects 38.7 55.2 39.2 12.8
Net Change in Cash -258.5 -274 416 81.4
Financing Cash Flow Items -0.1 -0.1
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Mérieux Family Other Insider Investor 58.9047 69720270 0 2022-12-13
Dassault Family Other Insider Investor 4.5964 5440410 0 2022-12-13 LOW
Sofina S.A. Investment Advisor/Hedge Fund 1.7293 2046857 0 2022-12-13 LOW
Oddo BHF Asset Management S.A.S Investment Advisor/Hedge Fund 1.3233 1566331 1216 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.0409 1232035 9165 2023-07-31 LOW
Candriam Luxembourg S.A. Investment Advisor 0.9457 1119401 14215 2023-06-30 MED
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.853 1009582 -23564 2022-12-31 LOW
Biomérieux Employees Corporation 0.7268 860200 0 2022-12-13
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6229 737243 -2778 2023-07-31 LOW
Devon Equity Management Ltd. Investment Advisor 0.5669 670995 0 2023-06-30 LOW
Amundi Asset Management, SAS Investment Advisor/Hedge Fund 0.5582 660731 1010 2023-07-31 LOW
La Financière de l'Echiquier Investment Advisor 0.5558 657855 -52897 2023-05-31 MED
DNCA Investments Investment Advisor 0.5365 635034 -54254 2023-06-30 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.5183 613458 3315 2023-07-31 LOW
Capital Research Global Investors Investment Advisor 0.5121 606183 -2266 2023-06-30 LOW
CPR Asset Management Investment Advisor 0.4756 562920 -5580 2023-06-30 MED
Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.3634 430154 -1 2023-06-30 LOW
AXA Investment Managers Paris Investment Advisor/Hedge Fund 0.3621 428545 15038 2023-06-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.3239 383343 0 2023-06-30 LOW
Zadig Asset Management L.L.P. Investment Advisor 0.3042 360000 -180000 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biomerieux Company profile

About BioMerieux SA

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.

Equity composition

9/2017, 3-for-1 stock split (Factor: 3).

Industry: Laboratory Diagnostic & Testing Substances

376, chemin de l'Orme
CRAPONNE
AUVERGNE-RHONE-ALPES 69280
FR

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

US100

14,560.60 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

26,546.60 Price
+0.890% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

XRP/USD

0.51 Price
-0.310% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Oil - Crude

92.68 Price
-0.380% 1D Chg, %
Long position overnight fee 0.0587%
Short position overnight fee -0.0806%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading